S&P 500   4,131.39 (-0.33%)
DOW   32,769.91 (-0.10%)
QQQ   319.85 (-0.59%)
AAPL   164.71 (-0.39%)
MSFT   280.01 (-1.03%)
META   170.76 (+2.18%)
GOOGL   117.27 (-0.17%)
AMZN   138.77 (-1.44%)
TSLA   876.06 (+1.34%)
NVDA   174.24 (-8.24%)
NIO   20.20 (-0.10%)
BABA   90.59 (-2.13%)
AMD   99.78 (-2.47%)
MU   61.53 (-1.49%)
T   18.06 (-1.58%)
CGC   3.16 (+17.04%)
GE   75.54 (+1.59%)
F   15.83 (+3.46%)
DIS   109.06 (+2.28%)
AMC   24.13 (+8.79%)
PYPL   96.01 (+0.72%)
PFE   49.24 (-0.06%)
NFLX   233.27 (+2.86%)
S&P 500   4,131.39 (-0.33%)
DOW   32,769.91 (-0.10%)
QQQ   319.85 (-0.59%)
AAPL   164.71 (-0.39%)
MSFT   280.01 (-1.03%)
META   170.76 (+2.18%)
GOOGL   117.27 (-0.17%)
AMZN   138.77 (-1.44%)
TSLA   876.06 (+1.34%)
NVDA   174.24 (-8.24%)
NIO   20.20 (-0.10%)
BABA   90.59 (-2.13%)
AMD   99.78 (-2.47%)
MU   61.53 (-1.49%)
T   18.06 (-1.58%)
CGC   3.16 (+17.04%)
GE   75.54 (+1.59%)
F   15.83 (+3.46%)
DIS   109.06 (+2.28%)
AMC   24.13 (+8.79%)
PYPL   96.01 (+0.72%)
PFE   49.24 (-0.06%)
NFLX   233.27 (+2.86%)
S&P 500   4,131.39 (-0.33%)
DOW   32,769.91 (-0.10%)
QQQ   319.85 (-0.59%)
AAPL   164.71 (-0.39%)
MSFT   280.01 (-1.03%)
META   170.76 (+2.18%)
GOOGL   117.27 (-0.17%)
AMZN   138.77 (-1.44%)
TSLA   876.06 (+1.34%)
NVDA   174.24 (-8.24%)
NIO   20.20 (-0.10%)
BABA   90.59 (-2.13%)
AMD   99.78 (-2.47%)
MU   61.53 (-1.49%)
T   18.06 (-1.58%)
CGC   3.16 (+17.04%)
GE   75.54 (+1.59%)
F   15.83 (+3.46%)
DIS   109.06 (+2.28%)
AMC   24.13 (+8.79%)
PYPL   96.01 (+0.72%)
PFE   49.24 (-0.06%)
NFLX   233.27 (+2.86%)
S&P 500   4,131.39 (-0.33%)
DOW   32,769.91 (-0.10%)
QQQ   319.85 (-0.59%)
AAPL   164.71 (-0.39%)
MSFT   280.01 (-1.03%)
META   170.76 (+2.18%)
GOOGL   117.27 (-0.17%)
AMZN   138.77 (-1.44%)
TSLA   876.06 (+1.34%)
NVDA   174.24 (-8.24%)
NIO   20.20 (-0.10%)
BABA   90.59 (-2.13%)
AMD   99.78 (-2.47%)
MU   61.53 (-1.49%)
T   18.06 (-1.58%)
CGC   3.16 (+17.04%)
GE   75.54 (+1.59%)
F   15.83 (+3.46%)
DIS   109.06 (+2.28%)
AMC   24.13 (+8.79%)
PYPL   96.01 (+0.72%)
PFE   49.24 (-0.06%)
NFLX   233.27 (+2.86%)

Ambarella Is A Buy For Patient Investors 

Ambarella Is A Buy For Patient Investors 

Ambarella Is A Perfect Fit For Q2 Portfolios 

Ambarella’s (NASDAQ: AMBA) shares have been under intense pressure over the past few quarters but we think the bottom is in. The stock price was under pressure due to fears of slowing growth, the impact of the Omicron variant, supply chain issues, and lockdowns in China but it looks like the worst is behind the company now. While the 2nd quarter results are expected to be impacted by those issues, not only is the supply chain starting to show signs of improvement but lockdowns in China have eased and production in the region is on the rise. In this scenario, we see not only improvement within the supply chain but a chance for the company to gain momentum and for revenue growth to reaccelerate. 

“During Q1, the pandemic flared up in China and the resulting lockdown disrupted customer production schedules and orders placed on us, as well as logistics in the greater Asia supply-chain. A majority of our customers’ products are manufactured in this region and subject to impacts from China-related supply-chain disruptions. We are seeing a similar degree of impact across both our automotive and IoT businesses, further complicating the pre-existing kitting issues we have discussed before,” says CEO Fermi Wang. 

Ambarella Has Strong Quarter, Guides Weak 

Ambarella had a strong quarter with both revenue and earnings in excess of the consensus. The problem is the guidance for Q2 is well below the Marketbeat.com consensus estimate and there may be downside risk in the number. Until then, the Q1 revenue of $90.31 million is up 28.8% versus last year and beat the consensus by 240 basis points. The strength was driven by demand in key growth markets including the higher-margin computer vision product line. 


Turning to the margin, the company was able to widen both the GAAP and the adjusted gross margin with the adjusted gross margin up 90 basis points YOY. The only bad news is that the operating margin narrowed but this is due primarily to one-off factors that are either non-material to results or will drive results down the road. Those being an increase in share-based compensation and a near-33% increase in R&D spending. 

As for the guidance, the guidance for both revenue and earrings is well below the consensus figure but not because the business is failing. If anything, demand for the products is growing so we see the weakness as a passing issue and not one that will impact share prices long. The risk for the market is that economic conditions will change enough over the next 6 to 12 weeks and offset the expected recovery in product availability. In that scenario, the entire stock market will be in for a deeper correction than what it has seen so far. 

The Analysts Are Still Buying Ambarella 

The analyst are still buying Ambarella but the price target is slipping. At least 7 of the 16 analysts covering the stock have come out to lower their price targets and this may not be the end of the trend. The good news is the Marketbeat.com consensus rating of firm Buy is holding steady in the 12, 3, and 1-month comparisons and is still 73% above the current price action. Even the low price target of $100 implies more than 15% of upside and we think that is the least of what investors can expect by the end of the year. 

Price action in AMBA fell in premarket trading and opened with a gap lower but buyers are already scooping up shares. The price action is confirming support at the $80 level and the short-term moving average and could easily move higher in the near term. The next hurdle will be resistance at the $102 level which we think will not last long. The risk for the market is resistance at the $120 which we think will cap gains unless there is positive news to support the market. 

Ambarella Is A Buy For Patient Investors 

Companies Mentioned in This Article

CompanyMarketRank™Current PricePrice ChangeDividend YieldP/E RatioConsensus RatingConsensus Price Target
Ambarella (AMBA)
2.595 of 5 stars
$87.70-1.5%N/A-121.81Moderate Buy$132.20
Compare These Stocks  Add These Stocks to My Watchlist 

Should you invest $1,000 in Ambarella right now?

Before you consider Ambarella, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Ambarella wasn't on the list.

While Ambarella currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Free Email Newsletter

Complete the form below to receive the latest headlines and analysts' recommendations for your stocks with our free daily email newsletter:

Most Read This Week

Recent Articles

Search Headlines:

Latest PodcastFind Investing Opportunities For The Rest of 2022

Today, Kate’s guest is Rhys Williams, chief investment officer for the Opportunistic All Cap Equity, a long-short strategy at Spouting Rock Asset Management.

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.